Accuray to present CyberKnife Robotic Radiosurgery System at ASTRO Meeting

NewsGuard 100/100 Score

Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that 40 accepted abstracts highlighting the use of the CyberKnife Robotic Radiosurgery System will be presented as posters and presentations at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place in San Diego from October 31-November 4.

Presentations related to CyberKnife radiosurgery cover a growing array of clinical indications including prostate, intracranial, head and neck, lung, renal, spine and optic, as well as technical presentations including two breast cancer studies and a cost-effectiveness analysis for pancreatic cancer. Additionally, three abstracts from ongoing Accuray-sponsored clinical studies will be presented, which include the inoperable lung cancer study, and the two prostate cancer studies.

Two talks on the use of CyberKnife radiosurgery for the treatment of prostate cancer will be presented on Tuesday, November 2 beginning at 11:45 a.m. PT:

  • Robert Meier, M.D., radiation oncologist and medical director for the Swedish Cancer Institute of Northwest Hospital in Seattle, will present a study on quality of life outcomes titled, "Stereotactic Radiotherapy for Organ-confined Prostate Cancer: Early Toxicity and Quality of Life Outcomes from a Multi-institutional Trial."
  • Alan J. Katz, M.D., radiation oncologist for Flushing Radiation Oncology and CyberKnife of Long Island in New York, will present a study titled, "Quality of Life and Efficacy for Stereotactic Body Radiotherapy for Treatment of Organ Confined Prostate Cancer." This study assessed the efficacy and toxicity of stereotactic radiosurgery for patients with organ-confined prostate cancer.

Accuray will be exhibiting at booth #1313 and will host in-booth presentations on topics ranging from CyberKnife applications and progress in respiratory tracking to the future of SRS and opportunities with Robotic IMRT.  Guest presenters include:

  • Allison Grow, M.D., Ph.D., radiation oncologist, Florida Radiation Oncology Group
  • Debra Freeman, M.D., radiation oncologist, CyberKnife Centers of Tampa Bay and Senior Manager, Clinical Applications at Accuray
  • Chad Lee, Ph.D., CK Solutions, Inc.
  • Alan Pollack, M.D., Ph.D., chair of the Department of Radiation Oncology, University of Miami and chief of service, Jackson Memorial Hospital
  • Lee McNeely, M.D., radiation oncologist, Creekside Cancer Care
  • Eric Lartigau, M.D., Ph.D., Professor of Radiation Oncology, the University of Lille
  • Donald Fuller, M.D., radiation oncologist, the CyberKnife Centers of San Diego and Radiation Medical Group
  • Charlie Ma, Ph.D., professor and director of Radiation Physics, Fox Chase Cancer Center

Accuray will also showcase the latest capabilities of its newest offering, the CyberKnife VSI System, launched at last year's ASTRO meeting. Additionally, a new technology, Lung Optimized Treatment, which is pending 510(k) clearance by the U.S. Food and Drug Administration (FDA), will be demonstrated. The new technology is designed to expand the CyberKnife System's ability to non-invasively track tumor motion and potentially offer the option of fiducial-free treatments for more lung cancer patients.

"Throughout the past year CyberKnife radiosurgery has achieved significant growth globally as demonstrated by the treatment of the 100,000th patient, installation of the 206th CyberKnife System and growing use of the technology for extracranial indications including prostate and lung," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "The research presented at ASTRO 2010 demonstrates the rapid adoption and expanding applications for CyberKnife radiosurgery as an evolving, patient-friendly cancer treatment."

ASTRO meeting attendees are invited to tour the nearby CyberKnife Centers of San Diego on Monday, November 1 and Tuesday, November 2. More information on these tours, the aforementioned in-booth presentations and CyberKnife posters and presentations of interest is available at www.accurayescalate.com.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New AI tool 'TORCH' successfully identifies cancer origins in unknown primary cases